ARS Pharmaceuticals Q3 EPS $(0.36) Misses $(0.31) Estimate, Sales $37.710M Miss $41.992M Estimate

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 30.77 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $37.710 million which missed the analyst consensus estimate of $41.992 million by 10.20 percent. This is a 16.03 percent increase over sales of $32.501 million the same period last year.